CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Material agreement
- 4 Grant or award Director acquired 10,632 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- 4 Gift President and CEO gave 50,000 shares (gift)
- 4 Open-market sale COFO and Secretary sold 2,937 shares at $13.58 ($39,884)
- 4 Planned sale Chief Medical Officer sold 3,743 shares at an average $13.81 ($51,684)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Option exercise Chief Medical Officer acquired 44,655 shares (option exercise)
- 4 Planned sale President and CEO sold 495,282 shares at $15.00 ($7,429,230)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
Page 4 of 40 · 789 filings